Citigroup’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-329,500
Closed -$17.8M 5964
2025
Q4
$17.8M Buy
+329,500
New +$15.9M 0.01% 1180
2025
Q3
Sell
-287,700
Closed -$13.3M 6097
2025
Q2
$13.3M Buy
287,700
+227,700
+380% +$11.2M 0.01% 1204
2025
Q1
$3.66M Buy
60,000
+35,000
+140% +$2.04M ﹤0.01% 2206
2024
Q4
$1.41M Hold
25,000
﹤0.01% 3085
2024
Q3
$1.29M Hold
25,000
﹤0.01% 3047
2024
Q2
$1.04M Sell
25,000
-1,000
-4% -$44.7K ﹤0.01% 2891
2024
Q1
$1.41M Sell
26,000
-213,000
-89% -$10.9M ﹤0.01% 2744
2023
Q4
$12.3M Buy
239,000
+10,100
+4% +$530K 0.01% 1117
2023
Q3
$13.3M Buy
228,900
+12,000
+6% +$735K 0.01% 972
2023
Q2
$13.9M Buy
216,900
+31,500
+17% +$2.11M 0.01% 981
2023
Q1
$12.9M Sell
185,400
-205,200
-53% -$14.5M 0.01% 1042
2022
Q4
$28.1M Sell
390,600
-251,600
-39% -$19M 0.02% 634
2022
Q3
$45.7M Buy
642,200
+428,200
+200% +$31.1M 0.03% 406
2022
Q2
$16.5M Sell
214,000
-610,800
-74% -$46.5M 0.01% 891
2022
Q1
$60.2M Buy
824,800
+139,800
+20% +$9.39M 0.04% 435
2021
Q4
$42.7M Buy
685,000
+169,700
+33% +$9.95M 0.02% 627
2021
Q3
$30.5M Buy
515,300
+312,800
+154% +$20.6M 0.02% 762
2021
Q2
$13.5M Buy
202,500
+131,800
+186% +$8.59M 0.01% 1230
2021
Q1
$4.46M Sell
70,700
-150,500
-68% -$9.36M ﹤0.01% 1864
2020
Q4
$13.7M Sell
221,200
-138,800
-39% -$8.53M 0.01% 1306
2020
Q3
$21.7M Sell
360,000
-86,400
-19% -$5.2M 0.01% 857
2020
Q2
$26.2M Sell
446,400
-742,500
-62% -$44.4M 0.02% 675
2020
Q1
$66.3M Sell
1,188,900
-423,600
-26% -$25.9M 0.06% 271
2019
Q4
$104M Sell
1,612,500
-58,700
-4% -$3.36M 0.07% 246
2019
Q3
$84.7M Buy
1,671,200
+354,300
+27% +$16.7M 0.07% 281
2019
Q2
$59.7M Sell
1,316,900
-481,200
-27% -$22.4M 0.05% 368
2019
Q1
$85.8M Buy
1,798,100
+205,800
+13% +$10.3M 0.08% 224
2018
Q4
$82.8M Buy
1,592,300
+98,900
+7% +$5.31M 0.08% 229
2018
Q3
$92.7M Sell
1,493,400
-704,000
-32% -$41.8M 0.08% 209
2018
Q2
$122M Buy
2,197,400
+421,300
+24% +$22.8M 0.11% 146
2018
Q1
$112M Sell
1,776,100
-170,000
-9% -$10.9M 0.09% 172
2017
Q4
$119M Buy
1,946,100
+73,500
+4% +$4.6M 0.1% 193
2017
Q3
$119M Buy
1,872,600
+434,600
+30% +$25.4M 0.1% 162
2017
Q2
$80.1M Sell
1,438,000
-371,100
-21% -$20.2M 0.07% 213
2017
Q1
$98.4M Buy
1,809,100
+550,700
+44% +$30.2M 0.09% 176
2016
Q4
$73.5M Buy
1,258,400
+505,500
+67% +$27.6M 0.07% 283
2016
Q3
$40.6M Buy
752,900
+439,700
+140% +$28.2M 0.04% 401
2016
Q2
$23M Buy
313,200
+2,400
+0.8% +$170K 0.02% 585
2016
Q1
$19.9M Sell
310,800
-150,600
-33% -$9.5M 0.02% 607
2015
Q4
$31.7M Sell
461,400
-1,588,500
-77% -$105M 0.03% 527
2015
Q3
$121M Buy
2,049,900
+1,732,500
+546% +$110M 0.11% 138
2015
Q2
$21.1M Sell
317,400
-27,700
-8% -$1.83M 0.02% 750
2015
Q1
$22.3M Sell
345,100
-365,200
-51% -$22.9M 0.02% 716
2014
Q4
$41.9M Sell
710,300
-351,900
-33% -$19.8M 0.04% 471
2014
Q3
$54.4M Buy
1,062,200
+220,400
+26% +$11M 0.05% 363
2014
Q2
$40.8M Buy
841,800
+471,500
+127% +$23.2M 0.04% 423
2014
Q1
$19.2M Sell
370,300
-416,800
-53% -$22.2M 0.02% 741
2013
Q4
$41.8M Sell
787,100
-88,600
-10% -$4.51M 0.04% 442
2013
Q3
$40.5M Buy
875,700
+41,500
+5% +$1.82M 0.04% 433
2013
Q2
$37.3M Buy
+834,200
New +$36.2M 0.04% 419

Other funds holding BMY

Citigroup's BMY Position: Q1 2026 in Review

Citigroup increased its Bristol-Myers Squibb (BMY) stake by 7.7% in Q1 2026, buying an estimated $10.7M and bringing the position to 2,561,350 shares worth $155M. The position accounts for 0.07% of the portfolio, ranked #270.

Citigroup first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $462M in Q4 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Citigroup held 2,561,350 shares of Bristol-Myers Squibb worth $155M as of Q1 2026.
  • Citigroup bought 183,928 Bristol-Myers Squibb shares in Q1 2026, an estimated $10.7M.
  • Bristol-Myers Squibb made up 0.07% of Citigroup's portfolio in Q1 2026, its #270 holding.
  • Citigroup first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Bristol-Myers Squibb position peaked at $462M in Q4 2022.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.